Comparative Analysis of Outcomes with HMA Plus Venetoclax Vs Intensive Chemotherapy in AML Patients Harboring Very-High Risk Cytogenetics
Authors
Luis Aguirre,
Jan BewersdorfYiwen Liu,
Rory Shallis,
Leora Boussi,
Andrius Žučenka,
Sylvain Garciaz,
Rebecca Bystrom,
Daniel DeAngelo,
Richard Stone,
Marlise Luskin,
Jacqueline Garcia,
Eric Winer,
Kelly Ling,
Evan Chen,
Martha Wadleigh,
Eytan Stein,
Aaron Goldberg,
Amer Zeidan,
Shai Shimony +18 authors
,
Maximilian Stahl Tip Tip